Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Gastroenterology · Gastrinoma

Long-Term Care: Monitoring and Managing Your Health

At a Glance

Long-term gastrinoma care combines personalized imaging and fasting gastrin tests with safe ongoing acid control. A rising gastrin level alone does not prove recurrence because proton pump inhibitor use, kidney function, and lab variation can affect results; MEN1 and nutrient or bone health may also need monitoring.

Living with a gastrinoma or Zollinger-Ellison Syndrome (ZES) is often a marathon, not a sprint. Because these tumors are typically slow-growing, the focus of your care will shift from the intensity of diagnosis to the rhythm of active surveillance [1][2]. This phase is designed to catch any changes early while ensuring that your acid-blocking treatment remains safe and effective for the long haul [3].

Long-Term Monitoring: What to Expect

Surveillance is not “one size fits all.” Your schedule will depend on whether your tumor was fully removed, if you have the MEN1 genetic syndrome, and the biological “grade” and stage of your tumor [4][5].

  • Imaging: Many patients undergo an MRI or CT scan every 6 to 12 months initially, but this schedule is individualized. If you have metastatic disease or an unresected tumor, these scans may be more frequent [1][6].
  • DOTATATE PET Scans: These highly sensitive “functional” scans are typically used selectively—for example, if your gastrin levels are rising but nothing shows up on a standard MRI, or to check if a new treatment is working [6][7].
  • Biochemical Checks: You will have regular blood tests for fasting serum gastrin (FSG) [8]. It is important to know that gastrin levels fluctuate. A true recurrence in gastrinoma can sometimes show up first as a rise in gastrin long before a physical tumor is visible on a scan [8]. However, gastrin is strongly affected by PPI dose, kidney function, and lab variation, so a rise alone does not diagnose recurrence.

Understanding Your Risk Profile

Doctors use several “risk markers” to determine how closely they need to watch your condition. While these numbers can sound high, they are simply tools to help your team stay ahead of the disease.

  1. Fasting Gastrin Levels: In one study of MEN1 patients, an initial gastrin level 20 times the upper limit of normal was associated with a more aggressive disease course [9]. This is used as a “risk-enrichment signal,” meaning it tells your doctor to consider monitoring you more intensively [9][10].
  2. Tumor Size: Tumors larger than 2 cm are generally considered higher risk for spreading to the lymph nodes or liver [4][11].
  3. WHO Grade & Ki-67: As covered in previous pages, a Grade 2 or 3 tumor (with a higher Ki-67 index) suggests cells are dividing more quickly and requires more vigilant follow-up [4][12].
  4. Liver Involvement: The presence of liver metastases at diagnosis is a primary factor in choosing more aggressive systemic treatments like PRRT or targeted therapy [13][14].

Life on Long-Term PPI Therapy

For many ZES patients, high-dose Proton Pump Inhibitors (PPIs) are a lifelong necessity. While you may hear about risks associated with PPIs in the general population, the math is different for you: the risk of a life-threatening ulcer from stopping your PPI far outweighs the long-term side effects of the medication [3][15].

To stay healthy on long-term therapy, your doctor may monitor for these “micronutrient” shifts based on your individual symptoms and dose:

  • Vitamin B12 Deficiency: About 21% of ZES patients on long-term acid suppression develop low B12 [16]. Your doctor may check your B12, methylmalonic acid, and homocysteine levels [16][17].
  • Magnesium and Iron: In rare cases, long-term PPI use can lower magnesium or iron levels [18][19]. If you experience muscle cramps or fatigue, let your team know so they can check your electrolytes [18].
  • Bone Health: Some observational studies suggest a link between long-term PPI use and a higher risk of fractures [20]. Your doctor may consider a bone density scan or ensure you are getting enough Vitamin D and calcium [21][22].

MEN1-Specific Surveillance

If your gastrinoma is part of the MEN1 syndrome, surveillance must look at the whole body. A comprehensive MEN1 plan includes monitoring blood calcium (for parathyroid tumors), evaluating pituitary hormones, and coordinating genetic counseling for your family.

Managing the Psychological Toll

Living with a rare, chronic condition like gastrinoma can lead to scanxiety—the intense anxiety that builds up before and after follow-up imaging [7]. Because ZES often involves a long road to diagnosis, it is normal to feel hyper-vigilant about every stomach ache.

Remember that “slow-growing” is a common phrase used for many well-differentiated tumors [2]. Even if your gastrin levels rise slightly, it does not mean your condition is out of control; it simply means it is time for your care team to review your test conditions and adjust your treatment plan if appropriate [8]. Open communication with a specialist who understands the unique nature of neuroendocrine tumors is your best tool for peace of mind.

Common questions in this guide

How often will I need follow-up scans after gastrinoma treatment?
The schedule depends on whether the tumor was removed, whether you have MEN1, and the tumor’s grade, stage, and spread. MRI or CT scans may be done every 6 to 12 months at first, while people with an unresected or metastatic tumor may need more frequent imaging. DOTATATE PET scans are usually added selectively.
Can a rising gastrin level mean that my gastrinoma has returned?
A rise in fasting gastrin can sometimes happen before a tumor is visible on imaging, but it does not prove recurrence by itself. Proton pump inhibitor dose, kidney function, and normal laboratory variation can change the result, so your clinician will interpret it with repeat testing and imaging.
Will I need to take a proton pump inhibitor for life with Zollinger-Ellison syndrome?
Many people with Zollinger-Ellison syndrome need high-dose proton pump inhibitor treatment for the long term. Stopping or lowering it without medical supervision can allow dangerous acid production and ulcers to return, so any dose change should be planned with your care team.
What health problems should be checked during long-term PPI treatment?
Depending on your dose and symptoms, your clinician may check vitamin B12 and related tests, magnesium, or iron. They may also review bone health and whether calcium and vitamin D intake is adequate, especially if fracture risk is a concern.
How does MEN1 change long-term gastrinoma monitoring?
MEN1 surveillance looks beyond the gastrinoma and may include blood calcium testing for parathyroid disease and evaluation of pituitary hormones. A long-term plan may also include genetic counseling and discussion of testing or surveillance for family members.
Which features can make a gastrinoma higher risk?
Features associated with closer monitoring include a tumor larger than 2 cm, a Grade 2 or 3 tumor, a higher Ki-67 index, liver metastases, or markedly elevated fasting gastrin. These findings help the care team plan surveillance and treatment but do not determine an individual outcome by themselves.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my initial gastrin levels, grade, and tumor size, what is my individualized schedule for follow-up scans?
  2. 2.How will we distinguish between a 'biochemical recurrence' (rising gastrin) and an actual tumor return on imaging, given my PPI use?
  3. 3.What specific symptoms would prompt us to check my vitamin B12, magnesium, or iron levels?
  4. 4.What are the specific 'rebound' symptoms I should look for if we ever safely decide to lower my PPI dose?
  5. 5.If I am in a 'watch and wait' period, at what exact size or gastrin threshold would we consider moving to surgery?
  6. 6.What is our long-term plan for monitoring my MEN1-related risks, like parathyroid or pituitary tumors?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Imaging of Pancreatic Neuroendocrine Neoplasms.

    Chiti G, Grazzini G, Cozzi D, et al.

    International journal of environmental research and public health 2021; (18(17)) doi:10.3390/ijerph18178895.

    PMID: 34501485
  2. 2

    Diagnosis and Management of Gastrointestinal Neuroendocrine Neoplasms.

    Gonzalez RS

    Surgical pathology clinics 2020; (13(3)):377-397 doi:10.1016/j.path.2020.04.002.

    PMID: 32773190
  3. 3

    Assessing for Multiple Endocrine Neoplasia Type 1 in Patients Evaluated for Zollinger-Ellison Syndrome-Clues to a Safer Diagnostic Process.

    Singh Ospina N, Donegan D, Rodriguez-Gutierrez R, et al.

    The American journal of medicine 2017; (130(5)):603-605 doi:10.1016/j.amjmed.2016.11.035.

    PMID: 28011308
  4. 4

    Risk Factors for Recurrence in Pancreatic Neuroendocrine Tumor and Size as a Surrogate in Determining the Treatment Strategy: A Korean Nationwide Study.

    Kwon W, Jang JY, Song KB, et al.

    Neuroendocrinology 2021; (111(8)):794-804 doi:10.1159/000511875.

    PMID: 33002889
  5. 5

    Time-trend and recurrence analysis of pancreatic neuroendocrine tumors.

    Kim H, Song KB, Hwang DW, et al.

    Endocrine connections 2019; (8(7)):1052-1060.

    PMID: 31252400
  6. 6

    A Reassessment of the Clinical Utility of 68Ga-DOTATATE PET/CT in Patients With Gastroenteropancreatic Neuroendocrine Tumors.

    Prela O, Caveney B, Strawderman M, et al.

    Journal of surgical oncology 2025; (131(7)):1336-1342 doi:10.1002/jso.28061.

    PMID: 39757730
  7. 7

    Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.

    Calabrò D, Argalia G, Ambrosini V

    Diagnostics (Basel, Switzerland) 2020; (10(12)) doi:10.3390/diagnostics10121059.

    PMID: 33297381
  8. 8

    De novo Gastrinoma: A Case Report.

    Barbosa A, Gomes F, Fonseca L, et al.

    GE Portuguese journal of gastroenterology 2020; (27(3)):192-196 doi:10.1159/000503073.

    PMID: 32509925
  9. 9

    Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG).

    van Beek DJ, Nell S, Pieterman CRC, et al.

    Journal of surgical oncology 2019; (120(6)):966-975 doi:10.1002/jso.25667.

    PMID: 31401809
  10. 10

    The future: diagnostic and imaging advances in MEN1 therapeutic approaches and management strategies.

    Manoharan J, Albers MB, Bartsch DK

    Endocrine-related cancer 2017; (24(10)):T209-T225 doi:10.1530/ERC-17-0231.

    PMID: 28790162
  11. 11

    Novel scoring system for recurrence risk classification of surgically resected G1/2 pancreatic neuroendocrine tumors - Retrospective cohort study.

    Zou S, Jiang Y, Wang W, et al.

    International journal of surgery (London, England) 2020; (74()):86-91 doi:10.1016/j.ijsu.2019.12.034.

    PMID: 31926324
  12. 12

    Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.

    Zhang P, Li YL, Qiu XD, et al.

    World journal of surgical oncology 2019; (17(1)):66 doi:10.1186/s12957-019-1606-8.

    PMID: 30975157
  13. 13

    Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines).

    Gaujoux S, Pattou F, Cadiot G, et al.

    World journal of surgery 2026; (50(5)):1300-1311 doi:10.1002/wjs.70303.

    PMID: 41862416
  14. 14

    Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence.

    Dong DH, Zhang XF, Lopez-Aguiar AG, et al.

    HPB : the official journal of the International Hepato Pancreato Biliary Association 2020; (22(2)):215-223 doi:10.1016/j.hpb.2019.05.020.

    PMID: 31235429
  15. 15

    Total gastrectomy for severe proton pump inhibitor-induced hypomagnesemia in a MEN1/Zollinger Ellison syndrome patient.

    Perrier M, Delemer B, Deguelte S, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021; (21(1)):236-239 doi:10.1016/j.pan.2020.12.002.

    PMID: 33309626
  16. 16

    Long-Term Proton Pump Inhibitor-Acid Suppressive Treatment Can Cause Vitamin B12 Deficiency in Zollinger-Ellison Syndrome (ZES) Patients.

    Ito T, Ramos-Alvarez I, Jensen RT

    International journal of molecular sciences 2024; (25(13)) doi:10.3390/ijms25137286.

    PMID: 39000391
  17. 17

    The Effects of Proton Pump Inhibitors in Acid Hypersecretion-Induced Vitamin B12 Deficiency: A Systematic Review (2022).

    Swarnakari KM, Bai M, Manoharan MP, et al.

    Cureus 2022; (14(11)):e31672 doi:10.7759/cureus.31672.

    PMID: 36545170
  18. 18

    Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors.

    Janett S, Camozzi P, Peeters GG, et al.

    Gastroenterology research and practice 2015; (2015()):951768 doi:10.1155/2015/951768.

    PMID: 26064102
  19. 19

    Iron deficiency anemia from iron malabsorption caused by proton pump inhibitors.

    Boxer M

    EJHaem 2020; (1(2)):548-551 doi:10.1002/jha2.96.

    PMID: 35845020
  20. 20

    Proton pump inhibitors, bone and phosphocalcic metabolism.

    Philippoteaux C, Paccou J, Chazard E, Cortet B

    Joint bone spine 2024; (91(5)):105714 doi:10.1016/j.jbspin.2024.105714.

    PMID: 38458487
  21. 21

    The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.

    Freedberg DE, Kim LS, Yang YX

    Gastroenterology 2017; (152(4)):706-715 doi:10.1053/j.gastro.2017.01.031.

    PMID: 28257716
  22. 22

    Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva.

    de la Coba Ortiz C, Argüelles Arias F, Martín de Argila de Prados C, et al.

    Revista espanola de enfermedades digestivas 2016; (108(4)):207-24 doi:10.17235/reed.2016.4232/2016.

    PMID: 27034082

This page is for informational purposes only and does not constitute medical advice about gastrinoma or Zollinger-Ellison syndrome. Your care team should personalize your scans, blood tests, MEN1 surveillance, and PPI plan.

Get notified when new evidence is published on pancreatic gastrinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.